Ten post jest także dostępny w języku: polski
Polski Bank Komorek Macierzystych (PBKM), one of the largest European players in its industry, has announced changes in its management board. Tomasz Baran became the Vice-President of the Management Board. Tomasz Oldak was appointed member of the Management Board.
Tomasz Baran is the new Vice-President
Tomasz Baran has been working for PBKM since 2010 as Sales and Marketing Director. Previously, he gained his professional experience in Pliva (currently Teva) as a medical representative, regional sales manager and product manager. He also worked for AstraZeneca Pharma Poland (as New Product Development Manager, Product Group Manager and Marketing Manager), Stiefel Polska and GSK (in the latter two companies as Marketing Manager).
He’s a doctor by education. Since 2012 he has been a member of the company’s management board. Since May 2016 he has been appointed for another term.
Four-person board of PBKM
Tomasz Oldak has been with PBKM for 13 years. He was a laboratory manager, technology director and laboratory director of the capital group. In 2017, he became Director of Research and Development. He is also a co-founder and member of the Management Board of the subsidiary of PBKM’s subsidiary: FamiCordTx. He is a doctor of biological sciences and his doctoral thesis concerned umbilical cord blood banking for clinical purposes. In the Centrum Onkologii im. Marii Sklodowskiej-Curie in Warsaw, he co-founded one of the first public cord blood banks in Poland.
After the changes described above, the PBKM board consists of four persons. The president is Jakub Baran. Marcin Radziszewski has also been a member of the Management Board since January 2018.
PBKM in 2020: Acquisitions as a priority
In 2020 Polski Bank Komorek Macierzystych will focus on acquisitions. They will be the main driver of income growth, according to an interview given by Jakub Baran to PAP. The company has a list of over 10 acquisition targets, with a total value of €70m. The list includes mainly European companies of various sizes. At a later stage. PBKM plans to integrate the group after the acquisitions and optimise costs.
In addition, a few percent organic growth in the number of new customers is planned for 2020. The company also wants to develop cancer therapy based on CAR-T technology in 3-5 indications this year. At the beginning of the year, FamiCordTx, a subsidiary of PBKM, purchased an exclusive license to use CAR-T technology from the American company iCell Gene Therapeutics. It is based on this license that the company wants to develop a project to introduce cancer immunotherapy to the market.
The PBKM Group has a 35% share in the European market. At the end of 2019, it stored nearly 308,000 of umbilical cord or tissue in the B2C and B2B segments.